Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients

More than half of deaths among hemodialysis patients are due to cardiovascular disease. This study examined whether intravenous administration of ferric carboxymaltose (FCM) has an impact on cardiovascular events in iron-deficient hemodialysis patients. We performed a retrospective study concerning...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2021-05, Vol.35 (3), p.1617-1624
Main Authors: Righini, Matteo, Dalmastri, Vittorio, Capelli, Irene, Orsi, Claudio, Donati, Gabriele, Pallotti, Maria Giovanna, Pedone, Chiara, Casella, Gianni, Chieco, Pasquale, LA Manna, Gaetano
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:More than half of deaths among hemodialysis patients are due to cardiovascular disease. This study examined whether intravenous administration of ferric carboxymaltose (FCM) has an impact on cardiovascular events in iron-deficient hemodialysis patients. We performed a retrospective study concerning patients undergoing hemodialysis in our center from September 2016 to December 2019. We identified those who began FCM therapy (FCM group) during this period and those who did not (control group). We analyzed clinical, echocardiographic and laboratory parameters at the beginning (t0) and after one year (t1), to detect differences between the two groups. We identified 53 patients for the FCM group and 19 for the control group. Median follow-up was 1 year±3 months for both groups. In the FCM group, we observed a reduction in the doses of erythropoiesis-stimulating agents (ESA) (p
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.12419